JP2008500277A5 - - Google Patents

Download PDF

Info

Publication number
JP2008500277A5
JP2008500277A5 JP2006552536A JP2006552536A JP2008500277A5 JP 2008500277 A5 JP2008500277 A5 JP 2008500277A5 JP 2006552536 A JP2006552536 A JP 2006552536A JP 2006552536 A JP2006552536 A JP 2006552536A JP 2008500277 A5 JP2008500277 A5 JP 2008500277A5
Authority
JP
Japan
Prior art keywords
cancer
days
human immunoglobulin
administration
formulated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006552536A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008500277A (ja
JP5220315B2 (ja
Filing date
Publication date
Priority claimed from US10/778,915 external-priority patent/US20050180979A1/en
Application filed filed Critical
Publication of JP2008500277A publication Critical patent/JP2008500277A/ja
Publication of JP2008500277A5 publication Critical patent/JP2008500277A5/ja
Application granted granted Critical
Publication of JP5220315B2 publication Critical patent/JP5220315B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006552536A 2004-02-13 2005-02-09 抗EpCAM免疫グロブリン Expired - Fee Related JP5220315B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/778,915 US20050180979A1 (en) 2004-02-13 2004-02-13 Anti-EpCAM immunoglobulins
US10/778,915 2004-02-13
PCT/EP2005/001307 WO2005080428A2 (en) 2004-02-13 2005-02-09 Anti-epcam immunoglobulins

Publications (3)

Publication Number Publication Date
JP2008500277A JP2008500277A (ja) 2008-01-10
JP2008500277A5 true JP2008500277A5 (https=) 2008-04-03
JP5220315B2 JP5220315B2 (ja) 2013-06-26

Family

ID=34838270

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552536A Expired - Fee Related JP5220315B2 (ja) 2004-02-13 2005-02-09 抗EpCAM免疫グロブリン

Country Status (23)

Country Link
US (3) US20050180979A1 (https=)
EP (2) EP2107071A3 (https=)
JP (1) JP5220315B2 (https=)
KR (1) KR101236224B1 (https=)
CN (1) CN1976951B (https=)
AT (1) ATE437186T1 (https=)
AU (1) AU2005215874B2 (https=)
BR (1) BRPI0507660A (https=)
CA (1) CA2555694C (https=)
DE (1) DE602005015544D1 (https=)
DK (1) DK1713830T3 (https=)
EA (1) EA011951B1 (https=)
ES (1) ES2328159T3 (https=)
IL (1) IL177069A (https=)
MX (1) MXPA06008942A (https=)
NO (1) NO339364B1 (https=)
NZ (1) NZ549125A (https=)
PL (1) PL1713830T3 (https=)
PT (1) PT1713830E (https=)
SI (1) SI1713830T1 (https=)
UA (1) UA87128C2 (https=)
WO (1) WO2005080428A2 (https=)
ZA (1) ZA200606083B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3351919A1 (en) 2003-01-24 2018-07-25 University of Utah Methods of predicting mortality risk by determining telomere length
WO2007008943A2 (en) 2005-07-08 2007-01-18 Xencor, Inc. Optimized anti-ep-cam antibodies
AU2007213920B2 (en) * 2006-02-09 2013-08-29 Amgen Research (Munich) Gmbh Treatment of metastatic breast cancer
DK2041181T3 (da) * 2006-06-08 2011-08-29 Helmholtz Zentrum Muenchen Specifikke proteaseinhibitorer og deres anvendelse i cancerterapi
EP1865001A1 (en) * 2006-06-08 2007-12-12 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Specific protease inhibitors and their use in cancer therapy
CA2682296C (en) * 2007-04-04 2017-02-28 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Anti-epcam antibody and uses thereof
CN102439171B (zh) 2008-12-22 2017-07-14 犹他大学研究基金会 单色多重定量pcr
WO2011032296A1 (en) * 2009-09-21 2011-03-24 Mount Sinai Hospital Methods and compositions for the diagnosis and treatment of thyroid cancer
EP2819695B1 (en) * 2012-03-02 2018-06-27 Academia Sinica ANTI-EPITHELIAL CELL ADHESION MOLECULE (EpCAM) ANTIBODIES AND METHODS OF USE THEREOF
CN103387990B (zh) * 2012-09-24 2016-01-06 厦门大学 上皮细胞粘附分子的核酸适体EpCAM B及其制备方法
CA2912216A1 (en) 2013-05-22 2014-11-27 Telomere Diagnostics, Inc. Measures of short telomere abundance
CN103275226B (zh) * 2013-06-09 2017-08-29 中国科学技术大学 特异性抗人上皮细胞粘附分子(EpCAM)的单克隆抗体的制备、鉴定及应用
CN106456748A (zh) * 2014-01-08 2017-02-22 小利兰·斯坦福大学托管委员会 小细胞肺癌的靶向疗法
WO2016108954A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
FI3377103T4 (fi) * 2015-11-19 2025-04-16 Revitope Limited Funktionaalinen vasta-ainefragmenttikomplementointi kaksikomponenttiselle järjestelmälle epätoivottujen solujen uudelleenohjattua tappamista varten
JP2019530431A (ja) 2016-07-26 2019-10-24 テッサ・セラピューティクス・プライベート・リミテッド キメラ抗原受容体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5853697A (en) * 1995-10-25 1998-12-29 The United States Of America, As Represented By The Department Of Health & Human Services Methods of treating established colitis using antibodies against IL-12
BRPI9809391B8 (pt) * 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6855544B1 (en) * 1999-04-15 2005-02-15 Crucell Holland B.V. Recombinant protein production in a human cell
US7605238B2 (en) * 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
EP1383785B1 (en) * 2001-05-03 2011-03-16 Merck Patent GmbH Recombinant tumor specific antibody and use thereof
US20030175268A1 (en) * 2002-01-11 2003-09-18 Saint-Remy Jean-Marie R. Method and pharmaceutical composition for preventing and/or treating systemic inflammatory response syndrome
PL375064A1 (en) * 2002-05-20 2005-11-14 Abgenix, Inc. Treatment of renal carcinoma using antibodies against the egfr

Similar Documents

Publication Publication Date Title
JP2008500277A5 (https=)
ES2981830T3 (es) Uso de riluzol, profármacos de riluzol o análogos de riluzol con inmunoterapias para tratar cánceres
JP2007500236A5 (https=)
JP2009506790A5 (https=)
JP2020515578A5 (https=)
JP2006522830A5 (https=)
JP2004501101A5 (https=)
JP2013533858A5 (https=)
RU2020115713A (ru) Конъюгаты анти-cd71 активируемое антитело - лекарственное средство и способы их применения
RU2021130306A (ru) Композиции il-12, нацеленные на edb
JP2014515763A5 (https=)
JP2012518686A5 (https=)
JP2009505676A5 (https=)
JP2010535713A5 (https=)
RU2013142004A (ru) Конъюгаты "антитело-лекарственное средство"
JP2011103891A5 (https=)
JP2021513536A5 (https=)
JP2021523170A5 (https=)
RU2007145489A (ru) Фармацевтические композиции и способы лечения рака и его метастазов
JP2015517523A5 (https=)
JP2018512402A5 (https=)
TW201536319A (zh) 抗腫瘤劑及抗腫瘤效果增強劑
CN116712539A (zh) 抗her2抗体药物偶联物和抗pd-1抗体联合在制备治疗肿瘤的药物中的用途
WO2021129616A1 (zh) 抗pd-1抗体和组蛋白去乙酰化酶抑制剂的药物组合及其用途、使用方法
JP2008154589A5 (https=)